What is it about?
MiR-30a, acted as tumor promising biomarker, is involved in various biological processes, including cell proliferation, apoptosis, invasion and metastasis, as well as drug resistance. Understanding the molecular mechanisms of miR-30a in cancer may represent a new direction to regulate the development of breast cancer.
Featured Image
Why is it important?
The present study demonstrates that the manipulation of miR-17-3p supposedly affects the cellular redox status due to its ability of targeting antioxidants. In the context, the inactivation of antioxidants by expressing miR-17-3p should increase ROS and enhance radiotherapeutic efficiency to treat aggressive tumors. This study highlights the rigorous evidence that demonstrated suppression of multiple mitochondrial antioxidants by a single miRNA, thereby providing a promising approach to improve radiotherapy for advanced PCa by targeting mitochondrial function.
Perspectives
Our results provide proof-of-concept evidence that inhibition of mitochondrial function by targeting its antioxidant defense system contributes to radiosensitization in advanced PCa cells.
Jin-Hai Tang
Nanjing Medical University
Read the Original
This page is a summary of: MiR-30a: A Novel Biomarker and Potential Therapeutic Target for Cancer, Journal of Oncology, August 2018, Hindawi Publishing Corporation,
DOI: 10.1155/2018/5167829.
You can read the full text:
Contributors
The following have contributed to this page
